Cytosorbents Corp (CTSO) Cash Flow Statement
Cytosorbents Corp (CTSO) generated -$9.1M of operating cash flow over the twelve months to 2026-06-30, spent $150000 on capital expenditure and had free cash flow of -$9.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTSOCytosorbents CorpFollow CTSO — free
—
Price chart with a free account
- Market cap
- 16.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.6 | -3.5 | -6.7 | -9.0 | -6.7 | -6.5 | -10.8 | -16.8 | -5.6 | -14.0 | -28.2 | -21.7 | -14.4 | -12.4 | -9.1 | |
| Capital expenditure | 0.0 | 0.0 | 0.2 | 0.4 | 0.1 | 1.0 | 0.7 | 0.7 | 0.7 | 3.6 | 6.1 | 0.5 | 0.3 | 0.2 | -0.2 | |
| Free cash flow | -3.6 | -3.5 | -6.8 | -9.5 | -6.9 | -7.5 | -11.5 | -17.5 | -6.3 | -17.6 | -34.3 | -22.2 | -14.7 | -12.5 | -9.3 | |
| Stock-based compensation | — | — | 0.7 | 0.4 | 2.8 | 3.3 | 4.4 | 1.7 | 3.5 | 4.0 | 3.4 | 4.2 | 3.8 | 2.8 | — |
USD millions · SEC XBRL
Cytosorbents Corp — questions
- What is Cytosorbents Corp's operating cash flow?
- -$9.1M over the twelve months to 2026-06-30.
- How much does Cytosorbents Corp spend on capital expenditure?
- $150000 over the twelve months to 2026-06-30.
- What is Cytosorbents Corp's free cash flow?
- -$9.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Cytosorbents Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.